NR4A1 and breast carcinoma: For example, no objective responses were observed in a previous trial of tremelimumab plus exemestane in hormone-receptor positive disease and responses to anti-PD-1/L1 in advanced hormone-receptor positive breast cancer have been similarly modest20,21.